Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma
Increased levels of the nuclear export protein, exportin 1 (XPO1), were demonstrated in multiple myeloma (MM) patients. Targeting XPO1 with selinexor (the selective inhibitor of nuclear export; SINE compound KPT-330) demonstrates broad antitumor activity also in patient cells resistant to bortezomib...
Main Authors: | Barbara Muz, Feda Azab, Pilar de la Puente, Yosef Landesman, Abdel Kareem Azab |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-08-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523317300554 |
Similar Items
-
A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma
by: Kinan Alhallak, et al.
Published: (2021-09-01) -
Selinexor in relapsed/refractory multiple myeloma
by: Joshua Richter, et al.
Published: (2020-06-01) -
E-selectin-targeting lipid nanoparticles improve therapeutic efficacy and reduce side effects of bortezomib in multiple myeloma
by: Mina Maksimos, et al.
Published: (2023-04-01) -
Treatment of multiple myeloma with selinexor: a review
by: Qianlei Huang, et al.
Published: (2024-01-01) -
Selinexor: Targeting a novel pathway in multiple myeloma
by: Clifton C. Mo, et al.
Published: (2023-08-01)